{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:57:40Z","timestamp":1792202260785,"version":"4.4.0"},"reference-count":147,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005888","name":"Medical University of Lodz","doi-asserted-by":"publisher","award":["503\/3-021-01\/503-31-001"],"award-info":[{"award-number":["503\/3-021-01\/503-31-001"]}],"id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005888","name":"Medical University of Lodz","doi-asserted-by":"publisher","award":["503\/3-011-01\/503-31-001"],"award-info":[{"award-number":["503\/3-011-01\/503-31-001"]}],"id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jpet.2025.103658","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T09:28:48Z","timestamp":1752571728000},"page":"103658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Beyond epilepsy: The expanding role of valproic acid in Alzheimer disease therapy \u2013 a review"],"prefix":"10.1016","volume":"392","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1012-6550","authenticated-orcid":false,"given":"Magdalena","family":"Markowicz-Piasecka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"Mi\u0142kowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9354-903X","authenticated-orcid":false,"given":"Santosh Kumar","family":"Adla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristiina M.","family":"Huttunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogus\u0142awa","family":"Pietrzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jpet.2025.103658_bib1","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s40263-014-0167-1","article-title":"Efficacy and safety of intravenous valproate for status epilepticus: a systematic review","volume":"28","author":"Trinka","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jpet.2025.103658_bib2","series-title":"Valproic acid","author":"Rahman","year":"2024"},{"issue":"10","key":"10.1016\/j.jpet.2025.103658_bib3","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.seizure.2014.06.015","article-title":"Survival analysis for valproic acid use in adult glioblastoma multiforme: a meta-analysis of individual patient data and a systematic review","volume":"23","author":"Yuan","year":"2014","journal-title":"Seizure"},{"issue":"14","key":"10.1016\/j.jpet.2025.103658_bib4","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.3390\/cancers13143409","article-title":"Valproic acid and breast cancer: state of the art in 2021","volume":"13","author":"Wawruszak","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.jpet.2025.103658_bib5","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/cncr.22891","article-title":"Valproic acid for the treatment of myeloid malignancies","volume":"110","author":"Kuendgen","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.jpet.2025.103658_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.brainresbull.2009.09.003","article-title":"Valproic acid as a promising agent to combat Alzheimer\u2019s disease","volume":"81","author":"Zhang","year":"2010","journal-title":"Brain Res Bull"},{"issue":"4","key":"10.1016\/j.jpet.2025.103658_bib7","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.eplepsyres.2014.02.005","article-title":"Valproic acid in normal therapeutic concentration has no neuroprotective or differentiation influencing effects on long term expanded murine neural stem cells","volume":"108","author":"Brunn","year":"2014","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.jpet.2025.103658_bib8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","article-title":"The neuropathological diagnosis of Alzheimer\u2019s disease","volume":"14","author":"DeTure","year":"2019","journal-title":"Mol Neurodegener"},{"issue":"1","key":"10.1016\/j.jpet.2025.103658_bib9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13195-024-01384-0","article-title":"Histone deacetylase inhibitors VPA and WT161 ameliorate the pathological features and cognitive impairments of the APP\/PS1 Alzheimer\u2019s disease mouse model by regulating the expression of APP secretases","volume":"16","author":"Zhang","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"7","key":"10.1016\/j.jpet.2025.103658_bib10","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.3390\/ijms23073660","article-title":"Histone deacetylase (HDAC) inhibitors: a promising weapon to tackle therapy resistance in melanoma","volume":"23","author":"Palamaris","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jpet.2025.103658_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116782","article-title":"Development of peptoid-based heteroaryl-decorated histone deacetylase (HDAC) inhibitors with dual-stage antiplasmodial activity","volume":"277","author":"Stopper","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"7","key":"10.1016\/j.jpet.2025.103658_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104052","article-title":"Restoring the epigenome in Alzheimer\u2019s disease: advancing HDAC inhibitors as therapeutic agents","volume":"29","author":"Pereira","year":"2024","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jpet.2025.103658_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113874","article-title":"Inhibition of histone deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer\u2019s disease: a review (2010-2020)","volume":"226","author":"Li","year":"2021","journal-title":"Eur J Med Chem"},{"issue":"24","key":"10.1016\/j.jpet.2025.103658_bib14","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"G\u00f6ttlicher","year":"2001","journal-title":"EMBO J"},{"key":"10.1016\/j.jpet.2025.103658_bib15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fnagi.2019.00062","article-title":"Valproic acid stimulates hippocampal neurogenesis via activating the Wnt\/\u03b2-Catenin signaling pathway in the APP\/PS1\/Nestin-GFP triple transgenic mouse model of Alzheimer\u2019s disease","volume":"11","author":"Zeng","year":"2019","journal-title":"Front Aging Neurosci"},{"issue":"3","key":"10.1016\/j.jpet.2025.103658_bib16","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3390\/cells9030619","article-title":"Valproic acid promotes early neural differentiation in adult mesenchymal stem cells through protein signalling pathways","volume":"9","author":"Santos","year":"2020","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.jpet.2025.103658_bib17","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/cns.12445","article-title":"Valproic acid modifies synaptic structure and accelerates neurite outgrowth via the glycogen synthase kinase-3\u03b2 signaling pathway in an Alzheimer\u2019s disease model","volume":"21","author":"Long","year":"2015","journal-title":"CNS Neurosci Ther"},{"issue":"12","key":"10.1016\/j.jpet.2025.103658_bib18","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1084\/jem.20081588","article-title":"Valproic acid inhibits A\u03b2 production, neuritic plaque formation, and behavioral deficits in Alzheimer\u2019s disease mouse models","volume":"205","author":"Qing","year":"2008","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.jpet.2025.103658_bib19","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13041-019-0525-5","article-title":"Restoring Wnt\/\u03b2-catenin signaling is a promising therapeutic strategy for Alzheimer\u2019s disease","volume":"12","author":"Jia","year":"2019","journal-title":"Mol Brain"},{"issue":"9","key":"10.1016\/j.jpet.2025.103658_bib20","doi-asserted-by":"crossref","first-page":"7092","DOI":"10.1007\/s12035-024-04003-z","article-title":"Therapeutic potential effect of glycogen synthase kinase 3 beta (GSK-3\u03b2) inhibitors in Parkinson disease: exploring an overlooked avenue","volume":"61","author":"Turkistani","year":"2024","journal-title":"Mol Neurobiol"},{"issue":"2","key":"10.1016\/j.jpet.2025.103658_bib21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1034\/j.1399-5618.2002.40201.x","article-title":"Glycogen synthase kinase-3\u03b2, mood stabilizers, and neuroprotection","volume":"4","author":"Li","year":"2002","journal-title":"Bipolar Disord"},{"issue":"2","key":"10.1016\/j.jpet.2025.103658_bib22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1006\/mcne.2002.1117","article-title":"Valproate regulates GSK-3-mediated axonal remodeling and synapsin i clustering in developing neurons","volume":"20","author":"Hall","year":"2002","journal-title":"Mol Cell Neurosci"},{"issue":"10","key":"10.1016\/j.jpet.2025.103658_bib23","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.3390\/cells10102773","article-title":"Coactivation of GSK3\u03b2 and IGF-1 attenuates amyotrophic lateral sclerosis nerve fiber cytopathies in SOD1 mutant patient-derived motor neurons","volume":"10","author":"Ting","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.jpet.2025.103658_bib24","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s12035-014-8751-4","article-title":"Valproic acid alleviates memory deficits and attenuates amyloid-\u03b2 deposition in transgenic mouse model of Alzheimer\u2019s disease","volume":"51","author":"Xuan","year":"2015","journal-title":"Mol Neurobiol"},{"issue":"9","key":"10.1016\/j.jpet.2025.103658_bib25","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.4103\/NRR.NRR-D-23-01633","article-title":"Enhanced autophagic clearance of amyloid-\u03b2 via histone deacetylase 6-mediated V-ATPase assembly and lysosomal acidification protects against Alzheimer\u2019s disease in vitro and in vivo","volume":"20","author":"Long","year":"2025","journal-title":"Neural Regen Res"},{"issue":"4","key":"10.1016\/j.jpet.2025.103658_bib26","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/neuonc\/nop005","article-title":"Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines","volume":"12","author":"Fu","year":"2010","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103658_bib27","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/embor.2008.222","article-title":"Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease","volume":"10","author":"Belyaev","year":"2009","journal-title":"EMBO Rep"},{"issue":"4","key":"10.1016\/j.jpet.2025.103658_bib28","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3233\/JAD-150379","article-title":"Impact of insulin degrading enzyme and neprilysin in Alzheimer\u2019s disease biology: characterization of putative cognates for therapeutic applications","volume":"48","author":"Jha","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.jpet.2025.103658_bib29","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.neuropharm.2017.09.031","article-title":"Valproic acid and its congener propylisopropylacetic acid reduced the amount of soluble amyloid-\u03b2 oligomers released from 7PA2 cells","volume":"128","author":"Williams","year":"2018","journal-title":"Neuropharmacology"},{"issue":"22","key":"10.1016\/j.jpet.2025.103658_bib30","doi-asserted-by":"crossref","first-page":"8751","DOI":"10.3390\/ijms21228751","article-title":"Can we treat neuroinflammation in Alzheimer\u2019s disease?","volume":"21","author":"S\u00e1nchez-Saras\u00faa","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.jpet.2025.103658_bib31","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.3390\/ijms23115938","article-title":"An overview of oxidative stress, neuroinflammation and neurodegenerative diseases","volume":"23","author":"Teleanu","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jpet.2025.103658_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2021.105046","article-title":"Development of grape polyphenols as multi-targeting strategies for Alzheimer\u2019s disease","volume":"147","author":"El Gaamouch","year":"2021","journal-title":"Neurochem Int"},{"issue":"3","key":"10.1016\/j.jpet.2025.103658_bib33","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1440-1746.2003.03284.x","article-title":"Intestinal inflammation alters the susceptibility to pentylenetetrazole-induced seizure in mice","volume":"19","author":"Riazi","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103658_bib34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrneurol.2010.178","article-title":"The role of inflammation in epilepsy","volume":"7","author":"Vezzani","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.jpet.2025.103658_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2021.105340","article-title":"Analysis of gut microbiota in patients with epilepsy treated with valproate: results from a three months observational prospective cohort study","volume":"162","author":"Gong","year":"2022","journal-title":"Microb Pathog"},{"issue":"17","key":"10.1016\/j.jpet.2025.103658_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713446","article-title":"Duality of valproic acid effects on inflammation, oxidative stress and autophagy in human eosinophilic cells","volume":"24","author":"Uzel","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.jpet.2025.103658_bib37","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/00023210-200317090-00003","article-title":"Antiepileptic drug-induced pharmacodynamic aggravation of seizures does valproate have a lower potential?","volume":"17","author":"Hirsch","year":"2003","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jpet.2025.103658_bib38","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.seizure.2019.06.021","article-title":"Outcomes of low-dose valproic acid treatment in patients with juvenile myoclonic epilepsy","volume":"70","author":"G\u00fcrer","year":"2019","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.jpet.2025.103658_bib39","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.neuroscience.2007.06.053","article-title":"Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity","volume":"149","author":"Chen","year":"2007","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.jpet.2025.103658_bib40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00109-018-1722-x","article-title":"Valproic acid exerts specific cellular and molecular anti-inflammatory effects in post-operative conjunctiva","volume":"97","author":"Seet","year":"2019","journal-title":"J Mol Med (Berl)"},{"issue":"4","key":"10.1016\/j.jpet.2025.103658_bib41","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1007\/s10753-017-0574-9","article-title":"Anti-inflammatory effects of valproic acid in a rat model of renal ischemia\/reperfusion injury: alteration in cytokine profile","volume":"40","author":"Amirzargar","year":"2017","journal-title":"Inflammation"},{"issue":"2-3","key":"10.1016\/j.jpet.2025.103658_bib42","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.eplepsyres.2009.02.003","article-title":"Effects of epilepsy and valproic acid on oxidant status in children with idiopathic epilepsy","volume":"84","author":"Yi\u015f","year":"2009","journal-title":"Epilepsy Res"},{"issue":"2","key":"10.1016\/j.jpet.2025.103658_bib43","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000098053","article-title":"The effects of carbamazepine, valproic acid and phenobarbital on the oxidative and antioxidative balance in epileptic children","volume":"57","author":"Aycicek","year":"2007","journal-title":"Eur Neurol"},{"issue":"5","key":"10.1016\/j.jpet.2025.103658_bib44","first-page":"991","article-title":"The effect of antiepileptic drug therapy on antioxidant enzyme activity and serum lipid peroxidation in young patients with epilepsy. Article in Polish","volume":"37","author":"So\u0142owiej","year":"2003","journal-title":"Neurol Neurochir Pol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103658_bib45","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1515\/JBCPP.2000.11.1.73","article-title":"Erythrocyte glutathione, glutathione peroxidase, superoxide dismutase and serum lipid peroxidation in epileptic children with valproate and carbamazepine monotherapy","volume":"11","author":"Y\u00fcksel","year":"2000","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"10.1016\/j.jpet.2025.103658_bib46","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/7954371","article-title":"Effects of valproate monotherapy on the oxidant-antioxidant status in Mexican epileptic children: a longitudinal study","volume":"2018","author":"Beltr\u00e1n-Sarmiento","year":"2018","journal-title":"Oxid Med Cell Longev"},{"issue":"2","key":"10.1016\/j.jpet.2025.103658_bib47","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3892\/etm.2020.8802","article-title":"Effect of valproic acid on oxidative stress parameters of glutamate-induced excitotoxicity in SH-SY5Y cells","volume":"20","author":"Terzio\u011flu","year":"2020","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.jpet.2025.103658_bib48","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.neulet.2016.12.017","article-title":"Valproic acid protects against MPP+-mediated neurotoxicity in SH-SY5Y cells through autophagy","volume":"638","author":"Zhang","year":"2017","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.jpet.2025.103658_bib49","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.diff.2021.12.002","article-title":"NRF2 activation protects against valproic acid-induced disruption of neurogenesis in P19 cells","volume":"123","author":"Piorczynski","year":"2022","journal-title":"Differentiation"},{"issue":"2","key":"10.1016\/j.jpet.2025.103658_bib50","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10545-008-0841-x","article-title":"Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review","volume":"31","author":"Silva","year":"2008","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"10.1016\/j.jpet.2025.103658_bib51","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/toxsci\/kfi185","article-title":"Valproic acid II: effects on oxidative stress, mitochondrial membrane potential, and cytotoxicity in glutathione-depleted rat hepatocytes","volume":"86","author":"Tong","year":"2005","journal-title":"Toxicol Sci"},{"issue":"3-4","key":"10.1016\/j.jpet.2025.103658_bib52","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.brainresbull.2011.03.006","article-title":"Valproate reduces tau phosphorylation via cyclin-dependent kinase 5 and glycogen synthase kinase 3 signaling pathways","volume":"85","author":"Hu","year":"2011","journal-title":"Brain Res Bull"},{"issue":"2","key":"10.1016\/j.jpet.2025.103658_bib53","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1128\/MCB.25.2.525-532.2005","article-title":"B56 regulatory subunit of protein phosphatase 2A mediates valproic acid-induced p300 degradation","volume":"25","author":"Chen","year":"2005","journal-title":"Mol Cell Biol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103658_bib54","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00702-002-0798-0","article-title":"Lithium, but not valproate, induces the serine\/threonine phosphatase activity of protein phosphatase 2A in the rat brain, without affecting its expression","volume":"110","author":"Tsuji","year":"2003","journal-title":"J Neural Transm (Vienna)"},{"issue":"4","key":"10.1016\/j.jpet.2025.103658_bib55","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/j.1471-4159.2009.06385.x","article-title":"Valproic acid induces functional heat shock protein 70 via class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation","volume":"111","author":"Marinova","year":"2009","journal-title":"J Neurochem"},{"issue":"2","key":"10.1016\/j.jpet.2025.103658_bib56","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000529915","article-title":"Antiepileptic drugs modulate Alzheimer-related tau aggregation in a neuronal activity-independent manner","volume":"52","author":"Ito","year":"2023","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"3","key":"10.1016\/j.jpet.2025.103658_bib57","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3892\/ol.2016.4880","article-title":"Valproic acid induces autophagy by suppressing the Akt\/mTOR pathway in human prostate cancer cells","volume":"12","author":"Xia","year":"2016","journal-title":"Oncol Lett"},{"issue":"1","key":"10.1016\/j.jpet.2025.103658_bib58","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.neulet.2010.07.004","article-title":"The role of p38 MAPK in valproic acid induced microglia apoptosis","volume":"482","author":"Xie","year":"2010","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.jpet.2025.103658_bib59","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.brainres.2017.12.018","article-title":"Acute in vivo effect of valproic acid on the GABAergic system in rat brain: a [11C]Ro15-4513 microPET study","volume":"1680","author":"Bertelsen","year":"2018","journal-title":"Brain Res"},{"issue":"suppl 2","key":"10.1016\/j.jpet.2025.103658_bib60","first-page":"17","article-title":"Pharmacology of valproate","volume":"37","author":"Owens","year":"2003","journal-title":"Psychopharmacol Bull"},{"issue":"2","key":"10.1016\/j.jpet.2025.103658_bib61","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1527-3458.2003.tb00249.x","article-title":"Valproate: past, present, and future","volume":"9","author":"Johannessen","year":"2003","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.jpet.2025.103658_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1341472","article-title":"Established and emerging GABAA receptor pharmacotherapy for epilepsy","volume":"15","author":"Richardson","year":"2024","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.jpet.2025.103658_bib63","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.3390\/ijms18081813","article-title":"Towards a better understanding of GABAergic remodeling in alzheimer\u2019s disease","volume":"18","author":"Govindpani","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.jpet.2025.103658_bib64","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/jnc.14345","article-title":"The GABAergic system as a therapeutic target for Alzheimer\u2019s disease","volume":"146","author":"Calvo-Flores Guzm\u00e1n","year":"2018","journal-title":"J Neurochem"},{"key":"10.1016\/j.jpet.2025.103658_bib65","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fnagi.2016.00031","article-title":"Implications of GABAergic neurotransmission in Alzheimer\u2019s disease","volume":"8","author":"Li","year":"2016","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"10.1016\/j.jpet.2025.103658_bib66","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0197-4580(94)00150-2","article-title":"Anticonvulsants attenuate amyloid beta-peptide neurotoxicity, Ca2+ deregulation, and cytoskeletal pathology","volume":"16","author":"Mark","year":"1995","journal-title":"Neurobiol Aging"},{"issue":"8","key":"10.1016\/j.jpet.2025.103658_bib67","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/archgenpsychiatry.2011.72","article-title":"Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease","volume":"68","author":"Tariot","year":"2011","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"10.1016\/j.jpet.2025.103658_bib68","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1471-4159.2004.02725.x","article-title":"The mood stabilizer valproic acid stimulates GABA neurogenesis from rat forebrain stem cells","volume":"91","author":"Laeng","year":"2004","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.jpet.2025.103658_bib69","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s40001-024-01779-7","article-title":"Role of GABA pathway in motor and non-motor symptoms in Parkinson\u2019s disease: a bidirectional circuit","volume":"29","author":"Alharbi","year":"2024","journal-title":"Eur J Med Res"},{"issue":"1","key":"10.1016\/j.jpet.2025.103658_bib70","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.neuroscience.2010.04.041","article-title":"Valproic acid enhances microglial phagocytosis of amyloid-\u03b21-42","volume":"169","author":"Smith","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.jpet.2025.103658_bib71","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.biopha.2018.06.080","article-title":"Valproic acid attenuates A\u03b225-35-induced neurotoxicity in PC12 cells through suppression of mitochondria-mediated apoptotic pathway","volume":"106","author":"Zhao","year":"2018","journal-title":"Biomed Pharmacother"},{"issue":"14","key":"10.1016\/j.jpet.2025.103658_bib72","doi-asserted-by":"crossref","first-page":"10678","DOI":"10.1074\/jbc.M109.057836","article-title":"Cell proliferation via down-regulation of the Alzheimer amyloid precursor protein","volume":"285","author":"Venkataramani","year":"2010","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.jpet.2025.103658_bib73","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1002\/term.2219","article-title":"Valproic acid enhances the neural differentiation of human placenta derived-mesenchymal stem cells in vitro","volume":"11","author":"Talwadekar","year":"2017","journal-title":"J Tissue Eng Regen Med"},{"issue":"9","key":"10.1016\/j.jpet.2025.103658_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagrm.2020.194597","article-title":"Sp4 controls constitutive expression of neuronal serine racemase and NF-E2- related factor-2 mediates its induction by valproic acid","volume":"1863","author":"Zhang","year":"2020","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"issue":"4","key":"10.1016\/j.jpet.2025.103658_bib75","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.neuroscience.2006.02.065","article-title":"Valproic acid induces caspase 3-mediated apoptosis in microglial cells","volume":"140","author":"Dragunow","year":"2006","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.jpet.2025.103658_bib76","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/sj.cdd.4401759","article-title":"Valproic acid induces extracellular signal-regulated kinase 1\/2 activation and inhibits apoptosis in endothelial cells","volume":"13","author":"Michaelis","year":"2006","journal-title":"Cell Death Differ"},{"issue":"6","key":"10.1016\/j.jpet.2025.103658_bib77","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00210-017-1357-4","article-title":"Protective effect of valproic acid in streptozotocin-induced sporadic Alzheimer\u2019 s disease mouse model: possible involvement of the cholinergic system","volume":"390","author":"Sorial","year":"2017","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103658_bib78","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/cns.12186","article-title":"Valproic acid reduces neuritic plaque formation and improves learning deficits in APPSwe\/PS1A246E transgenic mice via preventing the prenatal hypoxia-induced down-regulation of neprilysin","volume":"20","author":"Wang","year":"2014","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.jpet.2025.103658_bib79","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.neuroscience.2014.02.012","article-title":"Age-dependent effects of valproic acid in Alzheimer\u2019s disease (AD) mice are associated with nerve growth factor (NGF) regulation","volume":"266","author":"Noh","year":"2014","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/j.jpet.2025.103658_bib80","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/089198879300600404","article-title":"Sodium valproate in the treatment of behavioral disturbance in dementia","volume":"6","author":"Mellow","year":"1993","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103658_bib81","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1176\/jnp.7.3.314","article-title":"Valproate in the treatment of behavioral agitation in elderly patients with dementia","volume":"7","author":"Lott","year":"1995","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"9","key":"10.1016\/j.jpet.2025.103658_bib82","first-page":"430","article-title":"Divalproex sodium in the treatment of aggressive behavior and disphoria in patients with organic brain syndromes","volume":"56","author":"Horne","year":"1995","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.jpet.2025.103658_bib83","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00019442-199522330-00007","article-title":"Valproic acid for physically aggressive behavior in geriatric patients","volume":"3","author":"Sandborn","year":"1995","journal-title":"Am J Geriatr Psychiatry"},{"issue":"3","key":"10.1016\/j.jpet.2025.103658_bib84","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3109\/10401239709147789","article-title":"Divalproex: a possible treatment alternative for demented, elderly aggressive patients","volume":"9","author":"Haas","year":"1997","journal-title":"Ann Clin Pschiatry"},{"issue":"8","key":"10.1016\/j.jpet.2025.103658_bib85","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/j.1532-5415.1994.tb06571.x","article-title":"The effects of sodium valproate on disturbed behavior in dementia","volume":"42","author":"Sival","year":"1994","journal-title":"J Am Geriatr Soc"},{"issue":"12","key":"10.1016\/j.jpet.2025.103658_bib86","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0011-393X(97)80065-3","article-title":"A pilot study on the use of divalproex sodium in the treatment of behavioral agitation in elderly patients with dementia: assessment with the BEHAVE-AD and CGI rating scales","volume":"58","author":"Kasckow","year":"1997","journal-title":"Curr Ther Res Clin Exp"},{"issue":"4","key":"10.1016\/j.jpet.2025.103658_bib87","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/00019442-199700540-00010","article-title":"An open trial of valproate for agitation in geriatric neuropsychiatric disorders","volume":"5","author":"Porsteinsson","year":"1997","journal-title":"Am J Geriatr Psychiatry"},{"issue":"2","key":"10.1016\/j.jpet.2025.103658_bib88","first-page":"53","article-title":"Treatment of impulsivity and aggression in a patient with vascular dementia","volume":"56","author":"Buchalter","year":"2001","journal-title":"Geriatrics"},{"issue":"1","key":"10.1016\/j.jpet.2025.103658_bib89","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/(SICI)1099-1166(199801)13:1<29::AID-GPS726>3.0.CO;2-Z","article-title":"The efficacy and tolerability of divalproex sodium in elderly demented patients with behavioural disturbances","volume":"13","author":"Kunik","year":"1998","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.jpet.2025.103658_bib90","first-page":"63","article-title":"The use of adjunctive divalproex for neuroleptic unresponsive behavioural disturbances in nursing home residents with dementia","volume":"7","author":"Goldberg","year":"1999","journal-title":"Ann Long-Term Care"},{"issue":"1","key":"10.1016\/j.jpet.2025.103658_bib91","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00019442-200102000-00009","article-title":"Placebo-controlled study of divalproex sodium for agitation and dementia","volume":"9","author":"Porsteinsson","year":"2001","journal-title":"Am J Geriatr Psychiatry"},{"issue":"6","key":"10.1016\/j.jpet.2025.103658_bib92","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/gps.653","article-title":"Sodium valproate in the treatment of aggressive behavior in patients with dementia--a randomized placebo controlled clinical trial","volume":"17","author":"Sival","year":"2002","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1","key":"10.1016\/j.jpet.2025.103658_bib93","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0011-393X(01)80042-4","article-title":"Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double-blind, placebo-controlled trial","volume":"62","author":"Tariot","year":"2001","journal-title":"Curr Ther Res"},{"issue":"2","key":"10.1016\/j.jpet.2025.103658_bib94","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2165\/00023210-199402020-00007","article-title":"Valproic acid: review of its pharmacology and therapeutic potential in indications other than epilepsy","volume":"2","author":"Balfour","year":"1994","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.jpet.2025.103658_bib95","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000097757","article-title":"A placebo-controlled trial of valproate for agitation and aggression in Alzheimer\u2019s disease","volume":"23","author":"Herrmann","year":"2007","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"5","key":"10.1016\/j.jpet.2025.103658_bib96","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2174\/156720505774932205","article-title":"A randomized, double-blind, placebo-controlled pilot trial of safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer\u2019s disease","volume":"2","author":"Profenno","year":"2005","journal-title":"Curr Alzheimer Res"},{"issue":"11","key":"10.1016\/j.jpet.2025.103658_bib97","first-page":"942","article-title":"Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial","volume":"13","author":"Tariot","year":"2005","journal-title":"Am J Geriatr Psychiatry"},{"issue":"5","key":"10.1016\/j.jpet.2025.103658_bib98","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jalz.2011.05.2410","article-title":"Neuropsychiatric symptoms in Alzheimer\u2019s disease","volume":"7","author":"Lyketsos","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"12","key":"10.1016\/j.jpet.2025.103658_bib99","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1017\/S104161021300152X","article-title":"Adjustment, depression, and anxiety in mild cognitive impairment and early dementia: a systematic review of psychological intervention studies","volume":"25","author":"Regan","year":"2013","journal-title":"Int Psychogeriatr"},{"issue":"4","key":"10.1016\/j.jpet.2025.103658_bib100","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/00019442-200307000-00006","article-title":"Valproate therapy for agitation in dementia: open-label extension of a double-blind trial","volume":"11","author":"Porsteinsson","year":"2003","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"10.1016\/j.jpet.2025.103658_bib101","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.encep.2007.10.006","article-title":"Anticonvulsant mood stabilizers in the treatment of behavioral and psychological symptoms of dementia (BPSD). Article in French","volume":"34","author":"Pinheiro","year":"2008","journal-title":"Encephale"},{"issue":"2","key":"10.1016\/j.jpet.2025.103658_bib102","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003945.pub2","article-title":"Valproic acid for agitation in dementia","volume":"2","author":"Lonergan","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.jpet.2025.103658_bib103","article-title":"Valproate preparations for agitation in dementia","volume":"3","author":"Lonergan","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.jpet.2025.103658_bib104","article-title":"Valproate preparations for agitation in dementia","volume":"10","author":"Baillon","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jpet.2025.103658_bib105","series-title":"Sandoz Valproic. Product Monograph. Sandoz","year":"2018"},{"issue":"1","key":"10.1016\/j.jpet.2025.103658_bib106","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3390\/ijms25010390","article-title":"Valproic acid in pregnancy revisited: neurobehavioral, biochemical and molecular changes affecting the embryo and fetus in humans and in animals: a narrative review","volume":"25","author":"Ornoy","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.jpet.2025.103658_bib107","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/s41380-024-02732-0","article-title":"Valproic acid-induced teratogenicity is driven by senescence and prevented by Rapamycin in human spinal cord and animal models","volume":"30","author":"Pietrogrande","year":"2025","journal-title":"Mol Psychiatry"},{"issue":"6","key":"10.1016\/j.jpet.2025.103658_bib108","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1365-2125.1984.tb02401.x","article-title":"Pharmacokinetics of valproic acid in the elderly","volume":"17","author":"Perucca","year":"1984","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103658_bib109","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2125.1983.tb02151.x","article-title":"Pharmacokinetics of valproic acid in young and elderly subjects","volume":"16","author":"Bryson","year":"1983","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.jpet.2025.103658_bib110","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0022-3565(25)39013-0","article-title":"Contribution of probenecid-sensitive anion transport processes at the brain capillary endothelium and choroid plexus to the efficient efflux of valproic acid from the central nervous system","volume":"268","author":"Adkison","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"10.1016\/j.jpet.2025.103658_bib111","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2165\/00002512-200623110-00003","article-title":"Divalproex sodium for the treatment of behavioural problems associated with dementia in the elderly","volume":"23","author":"Porsteinsson","year":"2006","journal-title":"Drugs Aging"},{"issue":"13","key":"10.1016\/j.jpet.2025.103658_bib112","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1212\/WNL.0b013e318230a16c","article-title":"Chronic divalproex sodium use and brain atrophy in Alzheimer disease","volume":"77","author":"Fleisher","year":"2011","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jpet.2025.103658_bib113","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1631\/jzus.B1800340","article-title":"Valproic acid withdrawal ameliorates impairments of hippocampal-spatial working memory and neurogenesis","volume":"20","author":"Pannangrong","year":"2019","journal-title":"J Zhejiang Univ Sci B"},{"issue":"5","key":"10.1016\/j.jpet.2025.103658_bib114","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jalz.2010.04.006","article-title":"Alzheimer\u2019s disease, a multifactorial disorder seeking multitherapies","volume":"6","author":"Iqbal","year":"2010","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.jpet.2025.103658_bib115","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/jgs.18119","article-title":"Antiepileptic prescribing to persons living with dementia residing in nursing homes: a tale of two indications","volume":"71","author":"Candon","year":"2023","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"10.1016\/j.jpet.2025.103658_bib116","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jsps.2022.12.001","article-title":"A comprehensive review on pharmacological applications and drug-induced toxicity of valproic acid","volume":"31","author":"Safdar","year":"2023","journal-title":"Saudi Pharm J"},{"issue":"1-2","key":"10.1016\/j.jpet.2025.103658_bib117","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0006-8993(00)02893-6","article-title":"Probenecid-inhibitable efflux transport of valproic acid in the brain parenchymal cells of rabbits: a microdialysis study","volume":"884","author":"Scism","year":"2000","journal-title":"Brain Res"},{"issue":"5","key":"10.1016\/j.jpet.2025.103658_bib118","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/j.1471-4159.1985.tb08793.x","article-title":"Blood\u2013brain barrier transport of valproic acid","volume":"44","author":"Cornford","year":"1985","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.jpet.2025.103658_bib119","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1602\/neurorx.2.1.54","article-title":"Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems","volume":"2","author":"Tsuji","year":"2005","journal-title":"NeuroRx"},{"issue":"1","key":"10.1016\/j.jpet.2025.103658_bib120","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eplepsyres.2003.12.008","article-title":"Valproic acid uptake by bovine brain microvessel endothelial cells: role of active efflux transport","volume":"58","author":"Gibbs","year":"2004","journal-title":"Epilepsy Res"},{"issue":"8","key":"10.1016\/j.jpet.2025.103658_bib121","doi-asserted-by":"crossref","DOI":"10.1088\/1751-8113\/44\/8\/085201","article-title":"A \u201cmissing\u201d family of classical orthogonal polynomials","volume":"44","author":"Vinet","year":"2011","journal-title":"J Phys A: Math Theor"},{"key":"10.1016\/j.jpet.2025.103658_bib122","unstructured":"Therapeutics - Valproate [Internet]. Accessed March 10, 2025. https:\/\/www.alzforum.org\/therapeutics\/valproate"},{"issue":"3","key":"10.1016\/j.jpet.2025.103658_bib123","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.seizure.2005.01.008","article-title":"Complaints associated with the use of antiepileptic drugs: results from a community-based study","volume":"14","author":"Carpay","year":"2005","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.jpet.2025.103658_bib124","doi-asserted-by":"crossref","first-page":"37","DOI":"10.14336\/AD.2021.0529","article-title":"The cause of Alzheimer\u2019s disease: the theory of multipathology convergence to chronic neuronal stress","volume":"13","author":"Decourt","year":"2022","journal-title":"Aging Dis"},{"issue":"20","key":"10.1016\/j.jpet.2025.103658_bib125","article-title":"Unveiling the multifaceted pathogenesis and therapeutic drugs of Alzheimer\u2019s disease: a comprehensive review","volume":"10","author":"Peng","year":"2024","journal-title":"Helyion"},{"issue":"4","key":"10.1016\/j.jpet.2025.103658_bib126","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1590\/S1980-57642011DN05040011","article-title":"Factors influencing possible delay in the diagnosis of Alzheimer\u2019s disease: findings from a tertiary public university hospital","volume":"5","author":"de Miranda","year":"2011","journal-title":"Dement Neuropsychol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103658_bib127","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1017\/thg.2023.26","article-title":"The effect of genetic predisposition to Alzheimer\u2019s disease and related traits on recruitment bias in a study of cognitive aging","volume":"26","author":"Gomez","year":"2023","journal-title":"Twin Res Hum Genet"},{"issue":"2","key":"10.1016\/j.jpet.2025.103658_bib128","first-page":"8","article-title":"Environmental factors in the development of Alzheimer\u2019s disease","volume":"1","author":"Berestetska","year":"2023","journal-title":"Ann Innov Med"},{"issue":"23","key":"10.1016\/j.jpet.2025.103658_bib129","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.3390\/diagnostics14232640","article-title":"Etiology of late-onset Alzheimer\u2019s disease, biomarker efficacy, and the role of machine learning in stage diagnosis","volume":"14","author":"Sarma","year":"2024","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"10.1016\/j.jpet.2025.103658_bib130","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/molecules27010104","article-title":"Insights into structural modifications of valproic acid and their pharmacological profile","volume":"27","author":"Mishra","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.jpet.2025.103658_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115705","article-title":"Valproate, divalproex, valpromide: are the differences in indications justified?","volume":"168","author":"Delage","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"10.1016\/j.jpet.2025.103658_bib132","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/BF00549603","article-title":"Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers","volume":"27","author":"Bialer","year":"1984","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103658_bib133","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2125.1986.tb02886.x","article-title":"Valpromide inhibits human epoxide hydrolase","volume":"22","author":"Pacifici","year":"1986","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jpet.2025.103658_bib134","series-title":"Drugs During Pregnancy and Lactation","article-title":"Epilepsy and antiepileptic medications","author":"Chambers","year":"2015"},{"issue":"4","key":"10.1016\/j.jpet.2025.103658_bib135","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1399-5618.2010.00828.x","article-title":"Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial","volume":"12","author":"Bersudsky","year":"2010","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.jpet.2025.103658_bib136","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.yebeh.2015.04.012","article-title":"The potential of sec -butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus","volume":"49","author":"Shekh-Ahmad","year":"2015","journal-title":"Epilepsy Behav"},{"issue":"3A","key":"10.1016\/j.jpet.2025.103658_bib137","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/BF01962708","article-title":"Single-dose tolerance and pharmacokinetics of 2-n-propyl-2(E)-pentenoate (\u03942(E)-valproate) in healthy male volunteers","volume":"14","author":"D\u00fcsing","year":"1992","journal-title":"Pharm Weekbl Sci"},{"issue":"2-3","key":"10.1016\/j.jpet.2025.103658_bib138","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0014-2999(84)90243-7","article-title":"Comparative evaluation of anticonvulsant and toxic potencies of valproic acid and 2-en-valproic acid in different animal models of epilepsy","volume":"99","author":"L\u00f6scher","year":"1984","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"10.1016\/j.jpet.2025.103658_bib139","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ntt.2008.03.060","article-title":"Hydroxamic acid and fluorinated derivatives of valproic acid: anticonvulsant activity, neurotoxicity and teratogenicity","volume":"30","author":"Gravemann","year":"2008","journal-title":"Neurotoxicol Teratol"},{"issue":"8","key":"10.1016\/j.jpet.2025.103658_bib140","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.neuropharm.2005.06.008","article-title":"Efficacy of antiepileptic tetramethylcyclopropyl analogues of valproic acid amides in a rat model of neuropathic pain","volume":"49","author":"Winkler","year":"2005","journal-title":"Neuropharmacology"},{"issue":"25","key":"10.1016\/j.jpet.2025.103658_bib141","doi-asserted-by":"crossref","first-page":"6419","DOI":"10.1021\/jm7009233","article-title":"Potent anticonvulsant urea derivatives of constitutional isomers of valproic acid","volume":"50","author":"Shimshoni","year":"2007","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.jpet.2025.103658_bib142","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0920-1211(95)00044-5","article-title":"Effects of various valproic acid derivatives on low-calcium spontaneous epileptiform activity in hippocampal slices","volume":"22","author":"Armand","year":"1995","journal-title":"Epilepsy Res"},{"issue":"49","key":"10.1016\/j.jpet.2025.103658_bib143","doi-asserted-by":"crossref","first-page":"30781","DOI":"10.1039\/D1RA03718H","article-title":"The recent development of donepezil structure- based hybrids as potential multifunctional anti-Alzheimer\u2019s agents: highlights from 2010 to 2020","volume":"11","author":"Kareem","year":"2021","journal-title":"RSC Adv"},{"issue":"22","key":"10.1016\/j.jpet.2025.103658_bib144","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.3390\/molecules29225314","article-title":"New insights into the development of donepezil-based hybrid and natural molecules as multi-target drug agents for Alzheimer\u2019s disease treatment","volume":"29","author":"Angelova","year":"2024","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.jpet.2025.103658_bib145","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.3390\/ijms21061975","article-title":"Curcumin in health and diseases: Alzheimer\u2019s disease and curcumin analogues, derivatives, and hybrids","volume":"21","author":"Chainoglou","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.jpet.2025.103658_bib146","first-page":"10","article-title":"Efficacy of the combined use of donepezil with either quetiapine or sodium valproate in patients with Alzheimer\u2019s disease with behavioral and psychological symptoms of dementia, and their effects on vascular endothelial growth factors","volume":"21","author":"Yang","year":"2021","journal-title":"Exp Ther Med"},{"issue":"4","key":"10.1016\/j.jpet.2025.103658_bib147","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1080\/13607863.2016.1277974","article-title":"Perceptions vs. evidence: therapeutic substitutes for antipsychotics in patients with dementia in long-term care","volume":"22","author":"Olivieri-Mui","year":"2018","journal-title":"Aging Ment Health"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652539871X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652539871X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T01:17:16Z","timestamp":1777943836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652539871X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":147,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S002235652539871X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103658","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond epilepsy: The expanding role of valproic acid in Alzheimer disease therapy \u2013 a review","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103658","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103658"}}